2016
Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study
Dixon SC, Nagle CM, Thrift AP, Pharoah PD, Pearce CL, Zheng W, Painter JN, Study A, Chenevix-Trench G, Fasching P, Beckmann M, Lambrechts D, Vergote I, Lambrechts S, Van Nieuwenhuysen E, Rossing M, Doherty J, Wicklund K, Chang-Claude J, Rudolph A, Moysich K, Odunsi K, Goodman M, Wilkens L, Thompson P, Shvetsov Y, Dörk T, Park-Simon T, Hillemanns P, Bogdanova N, Butzow R, Nevanlinna H, Pelttari L, Leminen A, Modugno F, Ness R, Edwards R, Kelley J, Heitz F, Karlan B, Kjær S, Høgdall E, Jensen A, Goode E, Fridley B, Cunningham J, Winham S, Giles G, Bruinsma F, Milne R, Southey M, Hildebrandt M, Wu X, Lu K, Liang D, Levine D, Bisogna M, Schildkraut J, Berchuck A, Cramer D, Terry K, Bandera E, Olson S, Salvesen H, Thomsen L, Kopperud R, Bjorge L, Kiemeney L, Massuger L, Pejovic T, Cook L, Le N, Swenerton K, Brooks-Wilson A, Kelemen L, Lubiński J, Huzarski T, Gronwald J, Menkiszak J, Wentzensen N, Brinton L, Yang H, Lissowska J, Høgdall C, Lundvall L, Song H, Tyrer J, Campbell I, Eccles D, Paul J, Glasspool R, Siddiqui N, Whittemore A, Sieh W, McGuire V, Rothstein J, Narod S, Phelan C, Risch H, McLaughlin J, Anton-Culver H, Ziogas A, Menon U, Gayther S, Ramus S, Gentry-Maharaj A, Wu A, Pike M, Tseng C, Kupryjanczyk J, Dansonka-Mieszkowska A, Budzilowska A, Spiewankiewicz B, Webb P, Consortium O. Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal Of Epidemiology 2016, 45: 884-895. PMID: 27401727, PMCID: PMC5644573, DOI: 10.1093/ije/dyw158.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAllelesBody Mass IndexFemaleGenetic MarkersGenome-Wide Association StudyGenotypeHumansLogistic ModelsMendelian Randomization AnalysisMeta-Analysis as TopicMiddle AgedMultivariate AnalysisObesityOvarian NeoplasmsPolymorphism, Single NucleotideRisk FactorsYoung AdultConceptsBody mass indexOvarian cancerSerous cancerMass indexOdds ratioObservational studyMendelian randomizationStudy-specific odds ratiosHigher body mass indexAdult body mass indexGrade serous ovarian cancerConfidence intervalsOvarian cancer riskOvarian Cancer Association ConsortiumSerous ovarian cancerWeighted genetic risk scoreLack of associationMendelian randomization studyGenetic risk scoreStrength of associationHistological subtypesRisk factorsCancer riskRisk scoreHGSC subtype
2015
A Newly Identified Susceptibility Locus near FOXP1 Modifies the Association of Gastroesophageal Reflux with Barrett's Esophagus
Dai JY, de Dieu Tapsoba J, Buas MF, Onstad LE, Levine DM, Risch HA, Chow WH, Bernstein L, Ye W, Lagergren J, Bird NC, Corley DA, Shaheen NJ, Wu AH, Reid BJ, Hardie LJ, Whiteman DC, Vaughan TL. A Newly Identified Susceptibility Locus near FOXP1 Modifies the Association of Gastroesophageal Reflux with Barrett's Esophagus. Cancer Epidemiology Biomarkers & Prevention 2015, 24: 1739-1747. PMID: 26377193, PMCID: PMC4816532, DOI: 10.1158/1055-9965.epi-15-0507.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaBarrett EsophagusCase-Control StudiesEsophageal NeoplasmsFemaleForkhead Transcription FactorsGastroesophageal RefluxGenetic LociGenetic MarkersGenetic Predisposition to DiseaseGenome-Wide Association StudyHomozygoteHumansMalePolymorphism, Single NucleotideRepressor ProteinsRisk FactorsConceptsBody mass indexBarrett's esophagusEsophageal adenocarcinomaWeekly heartburnCase patientsSmoking statusMass indexRisk factorsSingle nucleotide polymorphismsMinor alleleBarrett's esophagus riskGene-exposure interactionsLeast weekly heartburnGastroesophageal reflux diseaseImportant risk factorGermline single nucleotide polymorphismsLogistic regression modelsExposure-disease associationsReflux symptomsGastroesophageal refluxReflux diseaseCigarette smokingSusceptibility single nucleotide polymorphismsOdds ratioEsophagusBiological and Clinical Significance of MAD2L1 and BUB1, Genes Frequently Appearing in Expression Signatures for Breast Cancer Prognosis
Wang Z, Katsaros D, Shen Y, Fu Y, Canuto EM, Benedetto C, Lu L, Chu WM, Risch HA, Yu H. Biological and Clinical Significance of MAD2L1 and BUB1, Genes Frequently Appearing in Expression Signatures for Breast Cancer Prognosis. PLOS ONE 2015, 10: e0136246. PMID: 26287798, PMCID: PMC4546117, DOI: 10.1371/journal.pone.0136246.Peer-Reviewed Original ResearchConceptsBreast cancer prognosisCancer prognosisGene expression signaturesExpression signaturesPoor disease-free survivalDisease-free survivalBreast cancer patientsBreast cancer cell linesBreast cancer progressionMDA-MB-468Tumor cell growthMDA-MB-231Multiple gene expression signaturesCancer cell linesAggressive tumorsCancer patientsClinical significanceDisease outcomeTumor featuresClinical implicationsPrognosisCancer progressionBiologic relevanceHigh expressionCell proliferation
2014
Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study
Lee AW, Tyrer JP, Doherty JA, Stram DA, Kupryjanczyk J, Dansonka-Mieszkowska A, Plisiecka-Halasa J, Spiewankiewicz B, Myers EJ, Study A, Group A, Chenevix-Trench G, Fasching PA, Beckmann MW, Ekici AB, Hein A, Vergote I, Van Nieuwenhuysen E, Lambrechts D, Wicklund KG, Eilber U, Wang-Gohrke S, Chang-Claude J, Rudolph A, Sucheston-Campbell L, Odunsi K, Moysich KB, Shvetsov YB, Thompson PJ, Goodman MT, Wilkens LR, Dörk T, Hillemanns P, Dürst M, Runnebaum IB, Bogdanova N, Pelttari LM, Nevanlinna H, Leminen A, Edwards RP, Kelley JL, Harter P, Schwaab I, Heitz F, du Bois A, Orsulic S, Lester J, Walsh C, Karlan BY, Hogdall E, Kjaer SK, Jensen A, Vierkant RA, Cunningham JM, Goode EL, Fridley BL, Southey MC, Giles GG, Bruinsma F, Wu X, Hildebrandt MA, Lu K, Liang D, Bisogna M, Levine DA, Weber RP, Schildkraut JM, Iversen ES, Berchuck A, Terry KL, Cramer DW, Tworoger SS, Poole EM, Olson SH, Orlow I, Bandera EV, Bjorge L, Tangen IL, Salvesen HB, Krakstad C, Massuger LF, Kiemeney LA, Aben KK, van Altena AM, Bean Y, Pejovic T, Kellar M, Le ND, Cook LS, Kelemen LE, Brooks-Wilson A, Lubinski J, Gronwald J, Cybulski C, Jakubowska A, Wentzensen N, Brinton LA, Lissowska J, Yang H, Nedergaard L, Lundvall L, Hogdall C, Song H, Campbell IG, Eccles D, Glasspool R, Siddiqui N, Carty K, Paul J, McNeish IA, Sieh W, McGuire V, Rothstein JH, Whittemore AS, McLaughlin JR, Risch HA, Phelan CM, Anton-Culver H, Ziogas A, Menon U, Ramus SJ, Gentry-Maharaj A, Harrington P, Pike MC, Modugno F, Rossing MA, Ness RB, Pharoah PD, Stram DO, Wu AH, Pearce CL. Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology 2014, 136: 542-548. PMID: 25528498, PMCID: PMC4892108, DOI: 10.1016/j.ygyno.2014.12.017.Peer-Reviewed Original ResearchConceptsOvarian cancer riskOvarian Cancer StudyCancer riskGene-level associationsOnly modest associationsUnconditional logistic regressionCancer studiesHormone-related diseasesPathway genesGonadotropin hypothesisEtiologic roleGenome-wide significant associationOvarian cancerProstate cancerLarger sample sizeGonadotropinSignificant associationDisease riskModest associationLogistic regressionGene-level testsHigh-penetrance susceptibility genesCandidate gene studiesStrong genetic basisUnderstanding of biology
2011
Genetic Effects and Modifiers of Radiotherapy and Chemotherapy on Survival in Pancreatic Cancer
Zeng H, Yu H, Lu L, Jain D, Kidd MS, Saif MW, Chanock SJ, Hartge P, Risch H. Genetic Effects and Modifiers of Radiotherapy and Chemotherapy on Survival in Pancreatic Cancer. Pancreas 2011, 40: 657-663. PMID: 21487324, PMCID: PMC3116071, DOI: 10.1097/mpa.0b013e31821268d1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overATP Binding Cassette Transporter, Subfamily G, Member 2ATP-Binding Cassette TransportersCase-Control StudiesConnecticutDihydrouracil Dehydrogenase (NADP)FemaleGenetic MarkersGenetic VariationGenome-Wide Association StudyHumansMaleMiddle AgedNeoplasm ProteinsPancreatic NeoplasmsPolymorphism, Single NucleotidePrognosisProportional Hazards ModelsSerpinsSurvival AnalysisTreatment OutcomeConceptsPancreatic cancerOverall survivalCancer survivalProportional hazards regression modelsSurvival of patientsPopulation-based studyPancreatic cancer survivalHazards regression modelsGerm-line genetic variationEvidence of associationClinical outcomesCancer patientsTreatment outcomesTreatment responseSignificant associationPatientsCancerPrevious genome-wide association study dataRadiotherapyPutative markerGenetic polymorphismsSurvivalDPYD geneChemotherapyEvidence of interaction
2010
A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk
Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB. A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk. Cancer Research 2010, 70: 6509-6515. PMID: 20647319, PMCID: PMC2923587, DOI: 10.1158/0008-5472.can-10-0689.Peer-Reviewed Original ResearchConceptsOvarian cancerKRAS-variantOC patientsCancer riskRisk of OCIndependent case-control analysesCase-control studyOvarian cancer syndromeCase-control analysisFamily membersAdvanced diseaseWomen's cancersRisk factorsBRCA2 mutationsHBOC patientsOC casesIndependent cohortHBOC familiesHereditary breastSolid tumorsCancer syndromesKRAS oncogeneVariant allelesPatientsCancer